The mitogen-activated protein kinase (MAPK) pathway is critical to oncogenic signaling in the majority of patients with malignant melanoma. Driver mutations in both NRAS and BRAF have important implications for prognosis and treatment. The development of inhibitors to mediators of the MAPK pathway, including those to CRAF, BRAF, and MEK, has led to major advances in the treatment of patients with melanoma. In particular, the selective BRAF inhibitor vemurafenib has been shown to improve overall survival in patients with tumors harboring BRAF mutations. However, the duration of benefit is limited in many patients and highlights the need for understanding the limitations of therapy in order to devise more effective strategies. MEK inhibitors have proven to particularly active in BRAF mutant melanomas also. Emerging knowledge about mechanisms of resistance as well as a more complete understanding of the biology of MAPK pathway signaling provides insight into rational combination regimens and sequences of molecularly targeted therapies.
INTRODUCTION
The mitogen-activated protein kinase (MAPK) pathway is activated in the great majority of melanomas and typically occurs through activating mutations of either NRAS (15-20% cutaneous melanomas) or BRAF (40-50%). 1 These mutations can be identified in benign melanocytic proliferation and all stages of invasive and metastatic melanoma. 1 Further, the presence of a BRAF mutation in the setting of metastatic disease has been associated with a poorer prognosis compared with patients whose tumors lack BRAF mutations in the era before BRAF inhibitors. In clinical trial cohorts, BRAF and MEK inhibitors appear to have neutralized the negative prognostic significance of a BRAF mutation and, in fact, their outcome may be superior to BRAF wild-type (BRAF WT ) melanoma in the metastatic setting. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] The effectiveness of the BRAF inhibition in terms of tumor regression and improved survival has led to FDA approval of vemurafenib (formerly PLX4032) and expected approval of dabrafenib (formerly GSK2118436) in 2012. As would be expected with single oncogene-directed therapies in genetically complex cancer, complete or durable responses are uncommonly seen with either vemurafenib or dabrafenib. Resistance to these agents typically occurs 6 to 8 months after initiation of therapy. For this reason, there is great interest in determining the mechanisms of resistance to these agents so that therapeutic strategies can be devised to prolong disease control or achieve complete responses more frequently. What follows is a review of MAPK pathway biology in melanoma, a brief summary of the clinical data with BRAF and MEK inhibitors in the treatment of patients with melanoma, a description of the emerging mechanisms of resistance to BRAF and MEK inhibition in these patients, and a discussion about some of the most promising strategies to overcome this resistance.
MELANOMA AND THE MAPK PATHWAY
Under normal physiological conditions, cell growth and survival is dependent on ligand-dependent growth factor receptor activation. The RAS GTPases are a critical link between activated growth factor receptors and downstream signal transduction pathways. In light of this central role, it is not surprising that three RAS isoforms (HRAS, KRAS and NRAS) collectively represent the most commonly mutated oncogene in human malignancies and distribute across a variety of cancers. 13, 14 In melanoma, NRAS mutations have been identified in 15-30% of tumor samples and are thought to be an important driver of oncogenesis in these patients, although the therapeutic value of targeting NRAS has yet to be demonstrated. [15] [16] [17] [18] The commonly observed NRAS mutations in melanoma disable the ability of the enzyme to hydrolyze guanosine triphosphate to guanosine diphosphate, leaving mutated NRAS predominantly guanosine triphosphatebound and capable of serial activation of the downstream components of the RAS effector pathways. 19 In the absence of RAS mutation, RAS activation can be aberrantly driven in melanoma through the autocrine or paracrine hyperactivation of growth factor receptors, such as c-Met, epidermal growth factor receptor and c-Kit. 13, 16, 18 In melanoma, the relative contribution of enhanced RAS effector pathway signaling in the setting of growth factor receptor activation or activating RAS mutation is unknown. But, there is substantial evidence to support the MAPK pathway as a critical component of oncogenic RAS signaling, although it is well established that NRAS can signal through non-MAPK pathways, such as the phospho-inositide-3-kinase (PI3K) pathway. In the MAPK pathway, however, the most important downstream mediators of activated RAS are BRAF and CRAF serine threonine kinases. 17 For mutated NRAS, CRAF appears to be relatively more essential for downstream activation of MAPKs. 19, 20 Considerably less is known about the role of ARAF in cancer. Both BRAF and CRAF contain a regulatory domain, which contains a RAS-binding domain (RBD) and a cysteine-rich domain (CRD), and a kinase domain which interact to suppress RAF function. 19, 21, 22 Activation of RAF (either B-or C-) could occur following RAS binding, through a disruption in the CRD-kinase domain negative regulatory interaction, thereby allowing for kinase activity. 23 However, cAMP influences which RAF isoform is predominantly activated and, in the presence of an NRAS mutation, CRAF is favored.
RAF, typically in the form of either homo-or heterodimerization, interacts with MEK, initiates MEK phosphorylation, and leads to phosphorylation and activation of ERK, its only known substrate. 17, 24, 25 The activation of ERK leads to a pro-growth and potentially transforming signal, through altered transcription of numerous genes. Feedback regulation of RAF kinases is mediated by Sprouty, and MEK and ERK are negatively regulated by dualspecificity phosphatases (DUSP4 and DUSP6). But in fully transformed melanoma, this feedback is dysregulated by poorly understood mechanisms and constitutive activation of ERK persists.
Although BRAF is thought to exert its oncogenic effects almost entirely through MEK, CRAF can lead to MEK-independendent prosurvival effects, in part through its interaction with nuclear factorkappa B (NF-kB), as well as through inhibitory effects of critical regulators of apoptosis, such as ASK-1 and MST-2. 17, 26, 27 Interestingly, unlike CRAF, activated BRAF has no known substrates other than MEK, although it is important to note that differential activation of substrates by ERK occurs depending upon the RAF isoform, and perhaps more specifically the RAF homo-or heterodimer, which leads to its activation. 28 For example, BRAF mutation (specifically BRAFV600E), and not CRAF upregulation, is associated with activating the mammalian target of rapamycin (mTOR) pathway through a deactivating phosphorylation of LKB-1 by ERK and regulating beta-Trcp, which leads to activation of NF-kB. 29, 30 These important consequences of oncogenic BRAF highlight the mechanisms by which an oncogene can influence pathways outside of the canonical pathways under the control of the wild-type form.
In CRAF, it appears that activation requires additional activation steps compared with BRAF. 31, 32 From an evolutionary perspective, this may explain why an activating mutation in the BRAF kinase domain is the 40-60% of patients with melanoma, whereas there are no descriptions of activating mutations of CRAF. 33 It is interesting to note that while BRAF mutations are seen in the great majority of melanocytic nevi (70-80%), vertical growth phase melanomas (40-50%) and metastatic melanoma (40-50%), one report suggested that they are rarely detected in radial growth-phase melanomas (10%), although this had been thought to be the precursor lesion before invasive tumors. [33] [34] [35] This suggests that BRAF mutation may actually be an acquired event, in some instances, in early invasive melanoma that leads to clonal expansion and tumor progression. The early occurrence of BRAF mutations likely accounts for the lack of polyclonality at this locus in metastatic melanoma. 1, 36 Somatic alterations in other pathways are essential for melanoma transformation. Inactivation of INK4A and PTEN are the best described cooperating events in vitro and in vivo. 37, 38 It is possible that heterogeneity exists within and across melanoma tumors with regarding INK4A and PTEN status, although this has not been thoroughly investigated. Despite the necessity of other oncogenic events in melanoma transformation, melanomas harboring BRAF mutations remain strictly reliant on MAPK pathway activation. 39 This cellular addiction to the pathway renders BRAF mutant cells susceptible to blockade of the pathway ( Figure 1 ).
NRAS and BRAF mutations and prognosis in melanoma
Recently, it has been shown that the prognosis of patients with melanoma is impacted depending on whether a patient 0 s tumor harbors either an NRAS or BRAF mutation. Specifically, both NRAS and BRAF mutational status is associated with a poorer prognosis in patients with stage IV melanoma compared with patients whose tumors are wild-type for both NRAS and BRAF. 6, 15 In particular, both a reduction of overall survival and a higher rate of brain metastases from the time of diagnosis from stage IV disease was noted. Interestingly, the prognostic significance of a BRAF mutation is confined to patients diagnosed with stage IV disease, while NRAS mutation is associated with a poorer prognosis from both initial diagnosis and stage IV diagnosis. Not surprisingly, given the clinical activity of BRAF-directed therapy (described below), patients with BRAF mutant, stage IV melanoma treated with a BRAF inhibitor have a better prognosis than NRAS mutant patients, BRAF mutant patients not treated with a BRAF inhibitor, and wild-type to both NRAS and BRAF patients.
Inhibitors of MAPK signaling in melanoma A series of small-molecule inhibitors have been developed, which target, with varying selectivity, BRAF V600E , other mutant BRAF variants (at the 600 position), wild-type BRAF and CRAF. In addition, inhibitors of the downstream mediators of RAF activation, namely MEK and ERK, are also being developed. In this section, only agents for which clinical data are available are reviewed (Table 1) .
BRAF INHIBITORS Sorafenib
Sorafenib, a broad-spectrum tyrosine and serine-threonine kinase inhibitor has inhibitory activity in vitro against BRAF, CRAF, platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor (VEGFR) 2, p38 and CKIT and was the first RAF-inhibitor actively studied in patients with melanoma as it was available for phase II testing in the same year in which BRAF mutations were first reported. 40 Unfortunately, despite being evaluated in numerous phase I, II and III studies as a single agent and in combination with chemotherapy, the clinical utility of sorafenib has been disappointing, as several trials of sorafenib both alone and in combination with various cytotoxic agents have revealed no substantial clinical benefit. [41] [42] [43] [44] [45] [46] [47] In comparing the results of serial tumor biopsies in a single-agent sorafenib trial to those now available with more potent and selective BRAF inhibitors, it is clear that sorafenib fails to inhibit the MAPK pathway adequately when administered at maximum tolerated doses. The maximum tolerated dose is most likely defined by toxicities arising from inhibition of kinases other than BRAF in normal tissues. This conclusion is supported by the similarity of sorafenib to other VEGF and PGDF receptor tyrosine kinase inhibitors with regard to common toxicities and the more recent clinical experience with more selective BRAF inhibitors.
Selective BRAF inhibitors (vemurafenib, dabrafenib) Following the failure of sorafenib in BRAF mutant melanoma, more potent and selective inhibitors of BRAF including vemurafenib and dabrafenib have been developed. 2, 4 Treatment with these agents leads to a reduction in levels of pERK in tumors containing the BRAF V600E mutation and degree of pERK inhibition correlates with clinical response. 48, 49 And, inhibition of the MAPK pathway is only observed in tumor cells harboring BRAF mutations, as other normal and cancer cells maintain MAPK signaling through CRAF. The differential effect on signaling likely contributes significantly to the therapeutic index of these more selective BRAF inhibitors. Both vemurafenib and dabrafenib are associated with some degree of tumor regression in 85% of patients and estimated progression-free survival rates of B5 À 6 months, which compares favorably to previously available therapies for metastatic melanoma. [2] [3] [4] 8, 10, 12, 50 Randomized, phase III trial results are now available for both vemurafenib and dabrafenib and each study clearly demonstrates a survival advantage for single-agent BRAF inhibition in comparison with the previous cytotoxic chemotherapy standard, dacarbazine.
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MEK INHIBITORS
Inhibitors of MEK have shown promise in preclinical studies in melanoma and, though the MAPK pathway is activated in most melanomas, BRAF V600E mutational status correlates strongly with response to MEK inhibition in murine melanoma xenograft models. 51 Clinically, several agents including selumetinib (AZD6244), PD-0325901, trametinib (GSK1120212), AS703026 and MEK162 have been evaluated in patients with melanoma with variable success.
5,7,9,52-56 The great majority of clinical benefit (defined as clinical response or improved survival) has been seen in patients with BRAF mutations, though emerging clinical evidence now has been described that supports a role of MEK inhibitors in treating patients with NRAS mutations. To date, none of the MEK inhibitors have resulted in clinical efficacy that is comparable to the selective BRAF inhibitors, though trametinib and MEK162 have recently been shown to be the most active MEK inhibitors thus far in BRAF mutant melanoma. 7, 9 This is likely due to the fact that MEK inhibitors block the MAPK pathway in normal tissues as well as in tumor, resulting in dose limiting toxicities as a consequence of MAPK pathway. Or, oncogenic BRAF has signaling effects mediated by as yet undiscovered substrates other than MEK.
Recently, MEK162 was shown to lead to responses in approximately a quarter of patients with NRAS mutations. 9 Although the duration of response and progression free survival were not dramatic, these findings support the continued investigation of this strategy in patients with NRAS mutations. In particular, MEK inhibitors will likely become the backbone of molecularly targeted therapy combinations for these patients.
Emerging mechanisms of resistance to BRAF-inhibition Virtually every patient treated with single agent BRAF or MEK inhibitors will eventually have disease progression despite initially profound inhibition of BRAF V600E , significant tumor regression and improved survival. 3 Preliminary studies suggest that a single resistance mechanism to vemurafenib and/or dabrafenib will not account for acquired resistance. To date, second mutations that impair the binding of the inhibitor BRAF have not been found; a resistance mechanism in non-small cell lung cancer, chronic myelogenous leukemia and gastrointestinal stromal tumor when treated with oncogene-directed therapies. [57] [58] [59] The best characterized resistance mechanisms typically reactivate the MAPK pathway through alternative means (Figure 2) .
The first evidence of BRAF-independent, MAPK pathway reactivating mechanisms came from BRAF V600E mutant cell lines cultured in the presence of a selective BRAF inhibitor until proliferation was observed in the presence of drug. In vitro, restoration of MAPK signaling is consistently observed. [60] [61] [62] [63] This can be achieved through upregulation of receptor tyrosine kinases (that is, PDGFRB, ERBB2), 61 ,62 activation of RAS, 60,62 upregulation of CRAF, 61, 63 activating mutations of MEK 64, 65 and activation of the Ser/Thr MAPKs (COT). 61 These can be considered within-pathway mechanisms that bypass BRAF as each can restore ERK activation despite ongoing BRAF inhibition. While resistance mutations in the kinase domain of BRAF have yet to be found either in vitro or in human tumor samples, alternative splicing of BRAF V600E has been identified in cell lines with acquired resistance and in a subset of melanoma tumor samples from patients who responded and then relapsed on BRAF inhibitor therapy. 66 The kinase domain is unaffected, but regulatory elements of BRAF, including the RAS binding site, are deleted resulting in a kinase that is capable of dimerizing and activating MEK even in the presence of a BRAF inhibitor. Most recently, BRAF amplification in progressing tumor samples from 4 of 20 patients that was not present at baseline has been reported. In vitro, forced overexpression of this confers BRAF V600E resistance to vemurafenib and other selective BRAF inhibitors, though this can be overcome with higher doses of BRAF inhibitors. 67 Resistance emerges in the face of ongoing MAPK suppression approximately one-third of the time. 48 In this setting, signaling through the parallel growth and survival PI3K pathway has been observed. Increased insulin growth factor receptor 1 (IGF-1R) signaling or acquired loss of PTEN have been correlated with increased activation of AKT. 68, 69 These are the bestdefined examples of MAPK-independent bypass mechanisms. 69 Of note, each of these mechanisms have been investigated and corroborated in small numbers of tumor samples from MAP kinase signaling and inhibition in melanoma RJ Sullivan and K Flaherty patients who had biopsies performed at the time of clinical progression. Primary resistance to BRAF inhibition is seen in o10% of patients with BRAF mutant melanoma treated with vemurafenib. Emerging evidence from both preclinical studies and analysis of pre-and on-treatment biopsies from patients treated with BRAFi suggest that PTEN loss, elevated pretreatment levels of CRAF, CCND1 amplification (with consequent cyclin D1 overexpression), CDK4-activating mutations, the receptor tyrosine kinase CMET expression and tumor microenvironment hepatocyte growth factor expression (the ligand for CMET) are promising predictive biomarkers that identify relative resistance to BRAF inhibitors and are worthy of validation. 63, [70] [71] [72] [73] Cyclin D and CDK4 alterations, PTEN loss, and hepatocyte growth factor expression all represent potential therapeutic opportunites given the emergence of selective CDK4/6 inhibitors (targeting Cyclin D and CDK4 alterations), PI3K inhibitors (PTEN loss), and anti-hepatocyte growth factor antibodies and/or CMET inhibitors (hepatocyte growth factor expression) that could be plausibly combined with BRAF inhibitors.
In BRAF wild-type melanoma cells, the MAPK pathway is activated by vemurafenib (and the analog PLX4720), leading to increased proliferation. 74, 75 This paradoxical effect appears to be CRAF dependent. 74 Further, CRAF activation appears to be mediated by enhanced dimer formation: heterodimers with wild-type BRAF and/or homodimers CRAF. 76 This phenomenon is most pronounced in RAS mutant cancer cell lines. Hyperactivation of the MAPK pathway in BRAF WT non-melanoma cells is likely responsible for some, if not most, of the toxicity of BRAF inhibitors. 11, 48 Paradoxically, it is likely this lack of MAPK pathway inhibition in BRAF WT tissues, which creates the ability to achieve the magnitude of MAPK inhibition in BRAF mutant tumors, needed to achieve clinical efficacy. Growth of cutaneous squamous cell carcinomas (SCCs) or keratoacantomas (KAs) has been observed early in the course of therapy in B25% of vemurafenib-treated patients.
3,10 Genetic analysis of 35 SCC/KAs which developed in patients treated with vemurafenib showed a mutation in either H-, K-or N-RAS in 21 (60%). 77 This compares with a much lower rate of HRAS mutation in sporadic SCC/KAs arising in heavily sun-exposed individuals. 78 Although not proven mechanistically in these resected SCC/KAs, it is likely that the observation of MAPK stimulation in RAS mutant cells accounts for the appearance of these lesions in patients treated with selective BRAF inhibitors.
From the perspective of acquired resistance, it is unclear what, if any, activation of CRAF homodimers or CRAF/BRAF heterodimers might have in cells that harbor a copy of BRAF V600E and BRAF WT . It is not thought that clinically acquired resistance to vemurafenib occurs solely due to growth of a subset of BRAF WT melanoma cells as persistence of the BRAF V600E mutation has been identified in all tumors analyzed and reported to date. 79, 80 It is possible that this mechanism favors the selection of tumor cells that harbor concomitant BRAF and NRAS mutations, a finding that has been seen in multiple series of patient samples at a rate of B15-25%. 66, 80 It is likely through activation of CRAF homodimers downstream of mutated NRAS that vemurafenib could contribute to growth of this subpopulation of tumor cells. 81 
FUTURE DIRECTIONS
The documentation of single-agent efficacy of selective BRAF inhibitors and MEK inhibitors is a major advance for the treatment of patients with BRAF mutation-positive melanoma. As nearly every patient treated with these agents is predicted to progress on treatment, identifying the mechanisms of this resistance has been a major focus of melanoma researchers over the past several years. Based on the finding that MAPK pathway activity is reactivated in melanoma following selective BRAF inhibition and that some BRAF inhibitor-associated toxicity might be abrogated by MEK inhibition, the first combination trial of a selective BRAF inhibitor (dabrafenib) with a MEK inhibitor (trametinib) is ongoing, appears tolerable with both agents being administered at their standard single-agent doses, and appears to be associated with a higher complete response rate, overall response rate and longer progression free survival than single agent BRAF inhibitors, though the results of a randomized phase II study comparing the combination to single agent dabrafenib are eagerly awaited. 11, 48 Another approach to enhancing the effectiveness of selective BRAF and/or MEK inhibitors is through careful analysis into why these agents induce benefit and then augment these responses with rationale combinations. For example, mutant BRAF modulates proapoptotic BCL-2 family members in melanoma, specifically triggering the inactivating phosphorylation of serine-75 of BAD as well as downregulating the expression of BIM, which together protect the cell from undergoing apoptosis. 82 Further, inhibition of BRAF or MEK, either through siRNA or small-molecule inhibitors, leads to growth inhibition and apoptosis at least in part through the upregulation of BIM and its associated suppression of activity of two antiapoptotic BCL-2 family members, BCL-2 and MCL-1. [83] [84] [85] [86] In particular, it appears that Bim induction and its subsequent sequestration of MCL-1, thereby leading to the activation of the mitochondrial associated proteins BAK and BAX, appears to the most critical factor for apoptosis induction following inhibition of MEK (and presumably BRAF). 82 Interestingly, loss of expression of phophatase and tensin homolog (PTEN), the key regulator of the PI3K pathway, is seen in 410% of mutated BRAF melanomas and appears to abrogate the effects of BRAF inhibitors through the suppression of BIM. 84 These findings are significant and provide the rationale for at least two novel combinations. First, the addition of agents that might augment BRAF and MEK inhibitor associated apoptosis is important to consider. One such agent is ABT-263, and to a lesser extent its less bioavailable homolog ABT-737, which is a BH3-mimetic currently in clinical development. ABT-263 and ABT-737 are small-molecule inhibitors of the anti-apoptotic proteins BCL-2, BCL-X L and BCL-w, which have been shown to have differential cytotoxicity against cell lines of several tumor types. 87, 88 Importantly, the cell lines most resistant to these agents showed overexpression of MCL-1 and pharmacological downregulation of MCL-1 potentiated the lethality of ABT-737 in these cell lines. 89 Thus combination of ABT-263 or similarly targeted agents with drugs that downmodulate or oppose MCL-1, such as BRAF or MEK inhibitors in BRAF mutant melanoma, represents an attractive therapeutic strategy. In preclinical studies, ABT-737 in combination with a MEK inhibitor led to enhanced lethality, in vitro and in vivo utilizing melanoma cell lines and xenografts, Figure 2 . Mechanisms of acquired resistance.
respectively, compared with either agent alone. 90 Whether ABT-263 in combination with MEK or selective BRAF inhibitors will improve clinical outcomes is unknown, though appears worth exploring in an early-phase clinical trial.
A second compelling combination that should be evaluated in patients is the combination of either a BRAF or MEK inhibitor in combination with an inhibitor of the PI3K pathway. While this is logical generally, given that the MAPK and PI3K pathways are the predominant signaling pathways utilized by human cancers, in melanoma there is specific justification. First, as was discussed above, PTEN loss suppresses BIM expression and appears to be an important mediator of tumor cell resistance to BRAF or MEK inhibition. 84 Further, PI3K activation via insulin growth factor receptor activation has been described as an acquired mechanism of resistance to BRAF inhibitors in clinical trials. 57 Thus, the concurrent or sequential inhibition of the PI3K pathway might be expected to enhance the clinical effectiveness of BRAF or MEK inhibitors.
In addition to combination therapy with molecularly targeted agents that inhibit signaling induced by selective BRAF inhibition or promote apoptosis, another promising approach to maximizing the benefit of BRAF or MEK inhibitors is to combine these agents with immunotherapy. Recently, immune checkpoint inhibitors, including the anti-CTLA-4 monoclonal antibody ipilimumab and the anti-PD monoclonal antibody MDX-1106, have shown single agent efficacy in patients with metastatic melanoma. [91] [92] [93] Importantly, it appears that vemurafenib does not adversely affect human T-lymphocyte (T-cell) function, whereas MEK inhibitors do. 94 Further, vemurafenib has been shown to improve immune recognition by antigen-specific T-cells and to induce T-cell infiltration in melanoma tumors. 95, 96 These findings provide a rationale for a study evaluating the safety and efficacy of selective BRAF inhibition in combination with immunotherapy, including ipilimumab, MDX1106 and possibly high-dose IL2.
CONCLUSIONS
It had been hoped for many years that the growing understanding of the molecular pathways involved in melanoma development and the increasing availability of specific inhibitors of these pathways would enable the rational development of future therapies.
With the emergence of vemurafenib and dabrafenib, the first molecularly targeted agents to lead to tumor responses in a large percentage of BRAF mutant patients, a new approach to the treatment of melanoma has begun. In those patients whose tumors harbor a mutation in BRAF, treatment with a highly potent BRAF inhibitor has become the standard of care. Importantly, the great majority of these patients will acquire resistance to BRAF inhibitors, and as the mechanisms of this resistance become elucidated, the development of combination trials of novel molecularly targeted therapies can be expected. Further clinical improvements will only be made through the careful conduction of preclinical and clinical studies.
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